Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|February 28, 2022

CORAL Study Brings Positive News for Adults With Depression

Author(s)Sagar V. Parikh, MD, FRCPC

Coadministration of zuranolone with a standard antidepressant yields positive outcomes.

Sagar Parikh, MD, FRCPC, shares news about the CORAL Study examining zuranolone treatment in patients with major depressive disorder, which demonstrated a rapid and statistically significant reduction in depressive symptoms at day 3 and over the 2-week treatment period.

To read more about this study, see: Improving Depression Symptoms: Study Meets Endpoints.

Dr Parikh is a professor of Depression and Clinical Neuroscience, and Psychiatry Sciences, at the University of Michigan.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

major depressive disorder osavampator

New Positive Phase 2 Data on Osavampator for Major Depressive Disorder

ByJessica Walters

September 23rd 2025

emotional blunting treatment resistant depression esketamine spravato

Positive Results of Analysis of Esketamine Nasal Spray on Emotional Blunting in Patients With Treatment-Resistant Depression

ByJessica Walters

September 21st 2025

lumateprone caplyta major depressive disorder anxious distress

Phase 3 Study of Lumateperone as Adjunct to Antidepressant Therapy for Major Depressive Disorder and Anxious Distress Meets End Points

ByJessica Walters

September 21st 2025

depression genetic marker ANK3 liafensine

New Biomarker-Guided Clinical Trial of Liafensine for Treatment-Resistant Depression

ByJessica Walters

September 18th 2025

depression treatment onfasprodil

Investigational Agent in Proof-of-Concept Trial Shows Rapid Improvement of Treatment-Resistant Depression

ByKenneth J. Bender, PharmD, MA

September 17th 2025

Latest CME

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment

Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment

Ilan Melnick, MD; Alejandro Alva, MD; Linda Trinh, DNP, PMHNP, FNP, MPH

PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia

PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia

Sanjai Rao, MD, DFAPA; Dawn I. Velligan, PhD

Southern Florida Psychiatry Conference

In-Person Event

Southern Florida Psychiatry Conference

November 21-22, 2025

Real Psychiatry 2026

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Optimizing Care for Patients With Tardive Dyskinesia

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

(CME Track) Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

(CME Track) Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CME Track) Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

(Pharmacist Track) Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(Pharmacist Track) Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

(Pharmacist Track) Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Trending on Psychiatric Times

The Trial of ChatGPT: What Psychiatrists Need to Know About AI, Suicide, and the Law

Preliminary Report on Dangers of AI Chatbots

6 Helpful Pearls From the International Guidelines for Algorithmic Treatment of Schizophrenia

Chatbots in Myth, Folktales, & Art

Fostering Resiliency in Mental Health Professionals: A Strengths-Based, Trauma-Informed Framework

© 2025 MJH Life Sciences^®

All rights reserved.